“From the first living donor kidney transplant at Cornell in 1963, Rogosin has pioneered the field of transplantation. Our active participation in kidney exchange for those with incompatible donors has helped propel us to being one of the most active transplant centers in the country. Our approach has always been to make our patients active members of the transplant team.”
David Serur, MD
Medical Director, Kidney and Pancreas Transplantation
The ideal treatment for patients with end stage renal disease is kidney transplantation because it offers patients an independent life that is free from dialysis. Rogosin performed New York State’s first living donor kidney transplant in 1963 and its first deceased donor transplant in 1965. Rogosin’s Immunogenetics and Transplantation Laboratory was the first in the metropolitan region, making it possible to match organs and allow more people to receive kidney transplants.
The Rogosin Institute’s Transplant program is carried out in collaboration with NewYork-Presbyterian/Weill Cornell and kidney and pancreas transplantation is available for adults and children. Rogosin’s one year survival rates are among the best in the nation at 96%. Transplantation is performed at NewYork-Presbyterian/Weill Cornell, with Rogosin’s transplant nephrologists managing the medical care of transplant patients before and after transplant surgery. Patients are part of the transplant team that includes nephrologists, surgeons, immunologists, nurses, pharmacists, technologists, social workers, dietitians and financial counselors.
Patients must meet certain basic criteria in order to be considered for a potential kidney transplant. All patients must be fully evaluated by the transplant team to determine if transplantation is the best treatment option. Transplant coordinators help guide all patients through the evaluation process.
Patients who have a kidney donor and are considered appropriate for a kidney transplant will work with the coordinator and team to schedule transplant surgery. Patients who have incompatible donors can participate in various donor exchange programs affiliated with the transplant program. Patients who do not have donors can still register for a deceased donor transplant at the NYP/Weill Cornell Program in cooperation with The Rogosin Institute.
Rogosin’s transplant program, in cooperation with NYP/Weill Cornell, helped facilitate 20% more transplants through kidney paired exchanges. Working with the National Kidney Registry to find and match donors with patients needing a transplant, we participated in the largest exchange ever - 30 transplants - and helped pioneer transplantation of live kidneys from coast to coast.
The Rogosin Institute and NYP/Weill Cornell make every effort to help patients who want and qualify for a transplantation, receive a successful kidney transplant.
The Rogosin Institute was involved in the early studies of immunosuppressive medications. These are the medications to help prevent rejection of the transplanted organ. Rogosin continues to improve treatments for transplant patients by advances in treatment protocols to decrease the need for these medications and to improve our already stellar success rates.
Rogosin’s Immunogenetics and Transplantation Laboratory is world-class and continuously evaluates tissue typing techniques.
For information about the Rogosin Institute and NYP/Weill Cornell Transplant program, call 212-746-3099.